Matthijs J Scheltema
Overview
Explore the profile of Matthijs J Scheltema including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
596
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Soeterik T, Heetman J, Hermsen R, Wever L, Lavalaye J, Vinken M, et al.
Eur Urol Oncol
. 2024 Nov;
PMID: 39613565
Background And Objective: The role of prostate-specific membrane antigen (PSMA)-based positron emission tomography (PET)/computed tomography (CT) in addition to magnetic resonance imaging (MRI) for local staging of prostate cancer (PC)...
2.
Geboers B, Scheltema M, Jung J, Bakker J, Timmer F, Cerutti X, et al.
BJU Int
. 2024 Aug;
135(2):319-328.
PMID: 39101639
Objectives: To prospectively compare systemic anti-tumour immune responses induced by irreversible electroporation (IRE) and robot-assisted radical prostatectomy (RARP) in patients with localised intermediate-risk prostate cancer (PCa). Patients And Methods: Between...
3.
Gondoputro W, Doan P, Katelaris A, Scheltema M, Geboers B, Agrawal S, et al.
Transl Androl Urol
. 2023 Nov;
12(10):1598-1606.
PMID: 37969779
Background: In active surveillance there is significant interest in whether imaging modalities such as multiparametric magnetic resonance imaging (mpMRI) or Gallium prostate-specific membrane antigen positron emission tomography/computerized tomography (Ga-PSMA-PET/CT) can...
4.
Geboers B, Meijer D, Counter W, Blazevski A, Thompson J, Doan P, et al.
BJU Int
. 2023 Oct;
133 Suppl 4:14-22.
PMID: 37858931
Objective: To evaluate the additional value of prostate-specific membrane antigen positron emission tomography (PSMA-PET) to conventional diagnostic tools to select patients for hemi-ablative focal therapy (FT). Patients And Methods: We...
5.
6.
Bodar Y, Boeve L, van Leeuwen P, Baars P, Nieuwenhuijzen J, van Haarst E, et al.
BJU Int
. 2023 Aug;
132(6):705-712.
PMID: 37620288
Objective: To assess whether a diagnostic pathway in which prostate-specific membrane antigen (PSMA) positron-emission tomography (PET)/computed tomography (CT) is used as a single imaging modality is feasible to guide targeted...
7.
Doan P, Katelaris A, Scheltema M, Hayen A, Amin A, Siriwardana A, et al.
BMC Urol
. 2023 Apr;
23(1):68.
PMID: 37118731
Purpose: To assess whether completeness of pelvic lymph node dissection (PLND) as measured by lymph node yield reduces biochemical recurrence (BCR) in men undergoing radical prostatectomy (RP) for prostate cancer...
8.
Scheltema M, Katelaris A, Stricker P
Nat Rev Urol
. 2023 Mar;
20(9):517-518.
PMID: 36859611
No abstract available.
9.
Geboers B, Scheltema M, Blazevski A, Katelaris A, Doan P, Ali I, et al.
BJU Int
. 2023 Jan;
131 Suppl 4:14-22.
PMID: 36594205
Objectives: To evaluate the safety, and short to mid-term oncological and quality-of-life (QoL) outcomes of focal irreversible electroporation (IRE) for radio-recurrent prostate cancer (PCa) at a median follow-up of 4 ...
10.
Blazevski A, Geboers B, Scheltema M, Gondoputro W, Doan P, Katelaris A, et al.
BJU Int
. 2022 Dec;
131 Suppl 4:23-31.
PMID: 36495482
Objectives: To prospectively assess the safety, functional- and oncological-outcomes of irreversible electroporation (IRE) as salvage therapy for radio-recurrent focal prostate cancer in a multicenter setting. Patients And Methods: Men with...